Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928496 · ClinicalTrials.gov registry record · Phase 4
Abobotulinumtoxina Efficacy in Post-Traumatic Headache
A Phase 4 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT03928496 is a Phase 4 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 40 participants.
The verdict
NCT03928496, a Phase 4 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache
Interventions
- DRUG Normal saline
- DRUG AbobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2017-02-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03928496
The ClinicalTrials.gov registry entry for NCT03928496 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT03928496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03928496 about?
NCT03928496 is a clinical study titled "Abobotulinumtoxina Efficacy in Post-Traumatic Headache". This study will evaluate the efficacy of abobotulinumtoxina on Veterans with post-traumatic headache
What is the current status of trial NCT03928496?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2013-08-01. Estimated completion is 2017-02-02.
What interventions are being tested in trial NCT03928496?
The interventions under investigation include: Normal saline (DRUG), AbobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT03928496?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.